What are the indications for a biventricular implantable cardioverter-defibrillator (CRT‑D)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Indications for Biventricular ICD (CRT-D)

A biventricular ICD (CRT-D) is indicated for patients with LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, and NYHA class II-IV symptoms on guideline-directed medical therapy, as this combination provides both resynchronization therapy to reduce mortality and hospitalizations while protecting against sudden cardiac death. 1

Class I Indications (Strongest Evidence)

Primary CRT-D Candidates

  • LVEF ≤35% with LBBB (QRS ≥150 ms): Patients in sinus rhythm with LBBB pattern, QRS duration ≥150 ms, and NYHA class II, III, or ambulatory IV symptoms on optimized GDMT should receive CRT-D to reduce total mortality, hospitalizations, and improve symptoms and quality of life. 1

  • High ventricular pacing requirement: For patients with LVEF ≤35% undergoing new or replacement device implantation who require >40% ventricular pacing, CRT-D is indicated to prevent pacing-induced cardiomyopathy and reduce mortality. 1

Class IIa Indications (Reasonable to Use)

Intermediate QRS Duration

  • LBBB with QRS 120-149 ms: In patients with LVEF ≤35%, sinus rhythm, LBBB pattern with QRS duration 120-149 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT, CRT-D is reasonable to reduce mortality and hospitalizations. 1, 2

Complete Heart Block with Preserved EF

  • LVEF 36-50% with complete heart block: CRT-D (or CRT-P) is reasonable for patients with high-degree or complete heart block and LVEF 36-50% to prevent pacing-induced cardiomyopathy and improve clinical outcomes. 1, 2

Atrial Fibrillation Patients

  • AF with LVEF ≤35%: CRT-D can be useful in patients with atrial fibrillation who meet standard CRT criteria, provided that either AV nodal ablation is performed or pharmacological rate control achieves near 100% ventricular pacing with CRT. 1

Class IIb Indications (May Be Considered)

Non-LBBB Patterns

  • Non-LBBB with QRS 120-149 ms: For patients with LVEF ≤35%, sinus rhythm, non-LBBB pattern with QRS 120-149 ms, and NYHA class III or ambulatory IV symptoms on GDMT, CRT-D may be considered, though evidence is weaker than for LBBB patterns. 1

Asymptomatic Ischemic Cardiomyopathy

  • NYHA class I with ischemic etiology: For patients with LVEF ≤30%, ischemic heart failure, sinus rhythm, LBBB with QRS ≥150 ms, and NYHA class I symptoms on GDMT, CRT-D may be considered to reduce future hospitalizations. 1

Genetic Arrhythmogenic Cardiomyopathy

  • High-risk genetic cardiomyopathy: In patients with genetic arrhythmogenic cardiomyopathy with high-risk features of sudden death and EF ≤45%, ICD (which may be combined with CRT if other criteria are met) is reasonable to decrease sudden death. 1

Absolute Contraindications

QRS Duration Threshold

  • QRS <120 ms: CRT-D is not recommended in patients with QRS duration <120 ms, regardless of echocardiographic evidence of dyssynchrony, as clinical trials have shown no benefit and potential harm. 1, 3

Symptom and QRS Combinations

  • NYHA I-II with non-LBBB and QRS <150 ms: CRT-D is not recommended for patients with NYHA class I or II symptoms and non-LBBB pattern with QRS <150 ms due to lack of demonstrated benefit. 1

Limited Life Expectancy

  • Survival <1 year: For patients whose comorbidities or frailty limit survival with good functional capacity to <1 year, CRT-D is not indicated as they will not derive meaningful benefit. 1

Critical Decision-Making Algorithm

Step 1: Verify LVEF and Optimize GDMT

  • Confirm LVEF ≤35% (or 36-50% for complete heart block) after at least 3 months of optimal guideline-directed medical therapy, as LVEF may improve with medical optimization alone. 1

Step 2: Assess QRS Duration and Morphology

  • Measure QRS duration on 12-lead ECG; strongest evidence exists for LBBB morphology with QRS ≥150 ms, with decreasing benefit as QRS shortens or with non-LBBB patterns. 1, 2

Step 3: Evaluate Rhythm

  • Sinus rhythm provides optimal CRT response; for atrial fibrillation patients, plan for AV nodal ablation or aggressive rate control to ensure near 100% biventricular pacing. 1

Step 4: Assess Functional Status

  • NYHA class II-IV symptoms indicate clear benefit; class I may benefit only if ischemic etiology with LVEF ≤30% and LBBB with QRS ≥150 ms. 1

Step 5: Determine ICD vs CRT-P

  • Choose CRT-D over CRT-P for patients meeting both CRT criteria and ICD criteria (primary prevention with LVEF ≤35% or secondary prevention after cardiac arrest/sustained VT). 3

Common Pitfalls and Caveats

Timing of Implantation

  • Avoid during acute decompensation: Do not implant CRT-D during admission for acute decompensated heart failure; optimize GDMT first and reassess LVEF after stabilization. 2

Pacing Percentage Requirements

  • Ensure high biventricular pacing: CRT-D benefit requires near 100% biventricular pacing; inadequate pacing percentage (<95-98%) negates the benefit, particularly in atrial fibrillation patients without adequate rate control. 1, 2

Right Ventricular Pacing-Induced Cardiomyopathy

  • Upgrade existing pacemakers: Patients with conventional right ventricular pacemakers who develop heart failure with LVEF ≤35% and high percentage ventricular pacing should be upgraded to CRT-D if they remain NYHA class III-IV despite adequate medical treatment. 2

QRS Morphology Matters

  • LBBB provides greatest benefit: The strongest evidence for CRT-D benefit exists in patients with typical LBBB morphology; non-LBBB patterns show less consistent benefit even with prolonged QRS duration. 2

Life Expectancy Assessment

  • Require >1 year survival: Patients should have reasonable expectation of survival with good functional status for >1 year to receive maximum benefit from CRT-D, considering both cardiac and non-cardiac comorbidities. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Indications for CRT-P in Complete Heart Block with LBBB

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cardiac Resynchronization Therapy for Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Can you explain the structure of the alveolo‑capillary (respiratory) membrane and the detailed mechanisms of gas exchange?
How should an anterior shoulder fluid pocket be evaluated and treated?
What is the most appropriate next step in managing a 45-year-old man with a BMI of 37 who presents with periumbilical pain that has migrated to right lower quadrant tenderness, afebrile, hemodynamically stable, and without nausea, vomiting, bowel habit changes, or urinary symptoms?
What are the anatomy, function, and clinical features of the abducens (VI) cranial nerve?
What is the recommended approach to evaluating and managing a patient with altered sensorium?
How should a 4-year-old boy with two days of fever and rash be evaluated and managed?
What are the annual ischemic stroke risks for each CHADS‑VASc score, including differences between men and women?
What is percutaneous coronary intervention (PCI)?
What is the recommended tetracycline dose and duration for treating peri‑oral dermatitis in an adult without contraindications?
When should cotrimoxazole (trimethoprim‑sulfamethoxazole) be used?
Provide a concise, unbiased neurologic summary for a 71‑year‑old male veteran with diabetes mellitus, coronary artery disease (prior ventricular tachycardia arrest on amiodarone), severe degenerative joint disease, a severe traumatic brain injury with spinal compression fractures, chronic post‑traumatic seizure disorder, progressive cognitive decline, spasticity of all limbs, Guillain‑Barré syndrome with persistent progressive symptoms, presenting with burning pain, numbness, paresthesias, weakness, loss of fine motor control, gait instability, frequent falls, bowel and urinary dysfunction, and currently taking amiodarone, clonazepam, pregabalin, baclofen, and insulin.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.